Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice

Pharmaceutical Research

Volumn 21, Issue 10, 2004, Pages 1867-1870

  Kalvass, J Cory ^a   Graff, Candace L ^a   Pollack, Gary M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

antinociception; CF 1 mice; loperamide; P glycoprotein; phenotyping

Indexed keywords

ANTINOCICEPTIVE AGENT; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG PENETRATION; GENE EXPRESSION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; GENOTYPE; LOPERAMIDE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHENOTYPE; REACTION TIME; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 6344291034     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000045241.26925.8b     Document Type: Article

References (15)

1. R. L. Juliano and V. Ling. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152-162 (1976).
2. P. L. Golden and G. M. Pollack. Blood-brain barrier efflux transport. J. Pharm. Sci. 92:1739-1753 (2003).
3. V. Ling. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol. 40:S3-S8 (1997).
4. P. F. Juranka, R. L. Zastawny, and V. Ling. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J. 3:2583-2592 (1989).
5. D. R. Umbenhauer, G. R. Lankas, T. R. Pippert, L. D. Wise, M. E. Cartwright, S. J. Hall, and C. M. Beare. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol. 146:88-94 (1997).
6. A. H. Schinkel, J. J. M. Smit, O. van Tellingen, J. H. Beijnen, E. Wagenaar, L. van Deemter, C. A. Mol, M. A. van der Valk, E. C. Robanus-Maandag, H. P. te Riele, A. J. Berns, and P. Borst. Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased senstivity to drugs. Cell 77:491-502 (1994).
7. P. Borst, A. H. Schinkel, J. J. M. Smit, E. Wagenaar, L. van Deemter, A. J. Smith, E. W. H. M. Eijdems, F. Baas, and G. J. R. Zaman. Classical and novel forms of multidrug resistance and the physiological functions of p-glycoproteins in mammals. Phamac. Ther. 60:289-299 (1993).
8. M. Narita, T. Suzuki, M. Misawa, and H. Nagase. Antagonism of the morphine-induced Straub tail reaction by k-opioid receptor activation in mice. Psychopharmacology (Berl.) 110:254-256 (1993).
9. C. Chen and G. M. Pollack. Blood-brain disposition and antinociceptive effects of -D-penicillamine2,5-enkephalin in the mouse. J. Pharmacol Exp. Ther. 283:1151-1159 (1997).
10. T. R. Pippert and D. R. Umbenhauer. The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene. J. Biochem. Mol. Toxicol. 15:83-89 (2001).
11. A. H. Schinkel, E. Wagenaar, C. A. Mol, and L. van Deemter. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin, Invest. 97:2517-2524 (1996).
12. A. J. Sadeque, C. Wandel, H. He, S. Shah, and A. J. Wood. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 68:231-237 (2000).
13. C. Pauli-Magnus, J. Feiner, C. Brett, E. Lin, and D. L. Kroetz. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin. Pharmacol. Ther. 74:487-498 (2003).
14. C. Skarke, M. Jarrar, H. Schmidt, G. Kauert, M. Langer, and G. Geisslinger, and J. Lotsch. Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13:651-660 (2003).
15. G. R. Lankas, M. E. Cartwright, and D. Umbenhauer. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 143:357-365 (1997).